SCHEMBL2471263

SCHEMBL2471263

CCOC(=O)c1c(-c2ccc(F)cc2)oc2cc(N(C)S(C)(=O)=O)ccc12

nearest known ligand 0.49

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
TP53 P04637 6/20 0.49
POLB P06746 1/20 0.49
KDM4E B2RXH2 6/20 0.48
MEN1 O00255 5/20 0.48
KMT2A Q03164 5/20 0.48
ALDH1A1 P00352 5/20 0.48
HPGD P15428 5/20 0.48
MAPT P10636 4/20 0.48
GAA P10253 2/20 0.48
TSHR P16473 2/20 0.48
HSD17B10 Q99714 2/20 0.48
HTT P42858 1/20 0.48
RCE1 Q9Y256 1/20 0.48
ALOX5 P09917 2/20 0.48
L3MBTL1 Q9Y468 1/20 0.46
PTGS2 P35354 2/20 0.45
PRNP P04156 1/20 0.45
NPSR1 Q6W5P4 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2401905 0.83 MEN1 (0.52) TP53KDM4EMEN1KMT2AALDH1A1
SCHEMBL5514943 0.82 CYP3A4 (0.52)
SCHEMBL2402762 0.81 MEN1 (0.55) TP53POLBKDM4EMEN1KMT2A
SCHEMBL12337405 0.81 MAPT (0.56) TP53POLBKDM4EMEN1KMT2A
SCHEMBL2530610 0.80 ALOX5 (0.55) KDM4EMEN1KMT2AALDH1A1HPGD
SCHEMBL2402733 0.80 ALOX5 (0.52) KDM4EMEN1KMT2AALDH1A1HPGD
SCHEMBL14709428 0.78 MEN1 (0.56) KDM4EMEN1KMT2AALDH1A1HPGD
SCHEMBL1918205 0.77 MEN1 (0.48) TP53KDM4EMEN1KMT2AALDH1A1
SCHEMBL1918033 0.76 ALOX5 (0.79) KDM4EMEN1KMT2AALDH1A1HPGD
SCHEMBL2402202 0.76 ALOX5 (0.48) KDM4EMEN1KMT2AALDH1A1HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2542545-A1 INHIBITORS OF HEPATITIS C VIRUS NS5B POLYMERASE Merck Sharp & Dohme Corp. (US) 2013-01-09 EP disclosed
US-20120328569-A1 INHIBITORS OF HEPATITIS C VIRUS NS5B POLYMERASE MERCK SHARP & DOHME CORP. 2012-12-27 US disclosed
US-20120328569-A1 INHIBITORS OF HEPATITIS C VIRUS NS5B POLYMERASE MERCK SHARP & DOHME CORP. 2012-12-27 US disclosed
WO-2011106992-A1 INHIBITORS OF HEPATITIS C VIRUS NS5B POLYMERASE MERCK SHARP & DOHME CORP. (US) 2011-09-09 WO disclosed
WO-2011106992-A1 INHIBITORS OF HEPATITIS C VIRUS NS5B POLYMERASE MERCK SHARP & DOHME CORP. (US) 2011-09-09 WO disclosed
WO-2011106929-A1 INHIBITORS OF HEPATITIS C VIRUS NS5B POLYMERASE MERCK SHARP & DOHME CORP. (US) 2011-09-09 WO disclosed
WO-2011106929-A1 INHIBITORS OF HEPATITIS C VIRUS NS5B POLYMERASE MERCK SHARP & DOHME CORP. (US) 2011-09-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120328569-A1 INHIBITORS OF HEPATITIS C VIRUS NS5B POLYMERASE HCCS, EIF2AK2, RNGTT TP53 3022/4885POLB 32/4885KDM4E 3818/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.